BlueLinx - BXC Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BlueLinx in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BXC shares.
View BXC analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1 year price targets for BlueLinx's shares. Their BXC share price forecasts range from $75.00 to $127.00. On average, they expect the company's stock price to reach $104.75 in the next twelve months. This suggests a possible upside of 36.1% from the stock's current price.
View analysts price targets for BXC or view top-rated stocks among Wall Street analysts.

BlueLinx's stock was trading at $95.76 at the beginning of 2022. Since then, BXC shares have decreased by 19.6% and is now trading at $76.97.
View the best growth stocks for 2022 here.

BlueLinx saw a increase in short interest in July. As of July 31st, there was short interest totaling 446,100 shares, an increase of 10.4% from the July 15th total of 403,900 shares. Based on an average trading volume of 180,300 shares, the days-to-cover ratio is presently 2.5 days. Approximately 5.0% of the company's shares are short sold.
View BlueLinx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our BXC earnings forecast.

BlueLinx Holdings Inc. (NYSE:BXC) posted its quarterly earnings results on Tuesday, August, 2nd. The construction company reported $7.48 earnings per share for the quarter, missing the consensus estimate of $7.64 by $0.16. BlueLinx had a trailing twelve-month return on equity of 79.52% and a net margin of 7.26%. During the same period last year, the business posted $11.61 earnings per share.

56 employees have rated BlueLinx Chief Executive Officer Mitch Lewis on Glassdoor.com. Mitch Lewis has an approval rating of 49% among the company's employees. This puts Mitch Lewis in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other BlueLinx investors own include Novavax (NVAX), Micron Technology (MU), Co-Diagnostics (CODX), Livongo Health (LVGO), Intel (INTC), Maxar Technologies (MAXR), Civeo (CVEO), Nautilus (NLS), Sorrento Therapeutics (SRNE) and Hologic (HOLX).

BlueLinx trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXC."

BlueLinx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Voss Capital LLC (4.77%), State Street Corp (1.88%), JPMorgan Chase & Co. (1.66%), Rock Creek Group LP (1.29%), Royce & Associates LP (1.27%) and DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (1.08%). Insiders that own company stock include Alexander S Averitt, Brian J Sasadu, Carol B Yancey, Kelly Janzen, Kim S Fennebresque, Mitchell B Lewis, Mitchell B Lewis, Nokomis Capital, LLC, Shyam K Reddy and Shyam K Reddy.
View institutional ownership trends.

Shares of BXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BXC stock can currently be purchased for approximately $76.97.

BlueLinx (NYSE:BXC) has a market capitalization of $743.38 million and generates $4.28 billion in revenue each year. The construction company earns $296.13 million in net income (profit) each year or $32.71 on an earnings per share basis.

The company employs 2,055 workers across the globe.

BlueLinx's mailing address is 1950 SPECTRUM CIRCLE SUITE 300, MARIETTA GA, 30067. The official website for the company is www.bluelinxco.com. The construction company can be reached via phone at (770) 953-7000, via email at ir@audentestx.com, or via fax at 770-221-8902.